GeneCentric Therapeutics to Present Data on Potential of its Cancer Subtyping Platform to Identify Responders to PARP Inhibitors for Treating Lung Cancer

DURHAM, N.C.--(BUSINESS WIRE)-- GeneCentric Therapeutics announced today that it will present data on the potential of non-small cell lung cancer (NSCLC) biologic subtypes based on its Cancer Subtyping Platform (CSP^®) to provide novel biomarkers for response to PARP inhibitors. The data will be presented at a poster session during the 2017 American Association for Cancer Research – National Cancer Institute - European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Therapeutics being held October 27-30, 2017 at the Philadelphia Convention Center, Philadelphia, PA.

GeneCentric’s core CSP technology is based on generating high resolution, genomic-defined cancer subtypes that characterize disease-related molecular pathways and immune cell expression, and employing the subtypes as biomarkers for response to specific drugs. To date the company has generated subtype-based profilers for NSCLC, head and neck, and bladder cancers.

In the research to be presented at the AACR-NCI-EORTC meeting company scientists evaluated the potential susceptibility of GeneCentric lung adenocarcinoma and lung squamous cell carcinoma gene expression subtypes to PARP inhibitors. By examining differential expression of homologous recombination genes and several previously published BRCAness signatures, the study identifies subtype-associated differences that might inform likely response to PARP inhibitors, an emerging class of drugs targeting DNA damage response. The researchers show that variable expression of DNA damage response genes in lung squamous cell carcinoma is maintained following adjustment for proliferation and BRCAness signatures, suggesting underlying biologic differences in lung squamous cell carcinoma subtype susceptibility to DNA damage response inhibitors. Confirmation of these findings via prospective cohorts could substantiate their utility as novel biomarkers for PARP inhibitor response.

Details of the presentation are as follows:

Title: “Differences in BRCAness/PARP inhibitor response signatures and homologous recombination
gene expression across lung adenocarcinoma and squamous cell carcinoma gene expression subtypes.”
Poster Number: 37
Abstract Number: A037
Date: Saturday, October 28, 2017
Time: 12:30 PM - 4:00 PM ET
Location: Hall E, Pennsylvania Convention Center
Presenter: Hawazin Faruki, DrPH, Chief Scientific Officer, GeneCentric

To read the abstract, please visit: http://www.abstractsonline.com/pp8/#!/4557/presentation/144

About GeneCentric

GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable development of precision medicine drugs and improve patient outcomes. Our approach applies the Cancer Subtype Platform (CSP^®) to parse complex tumor biology into genomic signatures revealing high-resolution cancer subtypes, with potential as universal biomarkers for susceptibility to multiple classes of agents including immune-based, molecularly targeted and chemotherapeutics. We are commercializing our technology through strategic collaborations with pharmaceutical and biotech companies to define responder populations applicable throughout the drug development cycle. GeneCentric has established several pharmaceutical collaborations, including an alliance with Bristol Myers Squibb in immuno-oncology. For more information, please visit www.genecentric.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171026006642/en/